Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2081-2085

  Crinò, Lucio ^a   Mosconi, Anna Maria ^a   Scagliotti, Giorgio ^a   Selvaggi, Giovanni ^a   Novello, Silvia ^a   Rinaldi, Massimo ^a   Della Giulia, Marina ^a   Gridelli, Cesare ^a   Rossi, Antonio ^a   Calandri, Cesare ^a   De Marinis, Filippo ^a   Noseda, Mariantonietta ^a   Tonato, Maurizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0032982848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2081     Document Type: Article

References (18)

1. Fossella FV, Lee SS, Kory WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24:455-462, 1997
2. Soquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
3. Non-Small Cell Lung Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
4. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 5:1087-1100, 1998
5. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
6. Ruiz van Haperen VWT, Veerman G, Eriksson S, et al: Development and characterization of a resistant variant of the human ovarian cancer cell line A2780. Cancer Res 54:4138-4143, 1994
7. Ruiz van Haperen VWT, Veerman G, Boven E, et al: Schedule-dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol 48:1327-1339, 1994
8. Veerman G, Van Moorsel CJA, Ruiz Von Haperen VWT, et al: Induction of in vivo resistance against gemcitabine (2′ 2′ difluorodeoxycytidine). Ann Oncol 7:122, 1996 (abstr 433) (suppl 1)
9. Bergman AM, Ruiz van Haperen, Veerman G, et al: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530, 1996
10. American Society of Clinical Oncology: Clinical Practice Guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15:2996-3018, 1997
11. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13:645-651, 1995
12. Gandara DR, Vokes E, Green M, et al: Multicenter trial of Docetaxel (taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival. Lung Cancer 18:21, 1997 (abstr 72) (suppl 1)
13. Pronzato P, Landucci M, Vaira F, et al: Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res 14:1413-1416, 1994
14. Rinaldi M, Della Giulia M, Venturo I, et al: Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 13:360, 1994 (abstr 12129)
15. Murphy WK, Win RJ, Huber M, et al: Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum-containing chemotherapy. Proc Am Soc Clin Oncol 13:363, 1994 (abstr 1224)
16. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer. J Clin Oncol 13:1609-1614, 1995
17. Rosvold E, Langer CJ, Schilder R, et al: Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel (C-P). Proc Am Soc Clin Oncol 17:467a, 1998 (abstr 1797)
18. Peters GJ, Ruiz van Haperen V, Bergman A, et al: Preclinical combination therapy with gemcitabine and mechanism of resistance. Semin Oncol 23:16-24, 1996 (suppl 10)